Cytokinetics (CYTK) Profit After Tax (2010 - 2026)
Cytokinetics (CYTK) posted quarterly Profit After Tax of -$208.3 million for Q1 2026, down 29.06% year-over-year from -$293.6 million in Q1 2025, and down 14.16% quarter-over-quarter from -$182.4 million in Q4 2025.
Cytokinetics (CYTK) Profit After Tax (2010 - 2026) Analysis & Trends
Cytokinetics (CYTK) has reported Profit After Tax for 17 consecutive years, with -$208.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Profit After Tax fell 29.06% year-over-year to -$208.3 million; the TTM figure through Mar 2026 stood at -$831.3 million (down 34.45% YoY), while the FY2025 annual figure was -$786.7 million, down 34.0% from the prior year.
- Profit After Tax fell to -$208.3 million in Q1 2026 per CYTK's latest filing, from -$182.4 million in the prior quarter.
- Across five years, Profit After Tax topped out at -$19.8 million in Q2 2022 and bottomed at -$306.2 million in Q3 2025.
- Historically, Profit After Tax has averaged -$147.0 million across 5 years, with a median of -$136.9 million in 2023.
- Annual changes were most pronounced in 2022 — Profit After Tax surged 67.8% — and 2023, when it plunged 549.03%.
- Cytokinetics' Profit After Tax stood at -$135.4 million in 2022, then slipped by 1.1% to -$136.9 million in 2023, then slipped by 11.77% to -$153.0 million in 2024, then declined by 19.23% to -$182.4 million in 2025, then fell by 14.16% to -$208.3 million in 2026.
- Business Quant data shows CYTK's Profit After Tax at -$208.3 million in Q1 2026, -$182.4 million in Q4 2025, and -$306.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 472.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,087.27 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -16.62 Mn |
| 10 | Cytokinetics | 10.31 Bn | 9.14 Bn | 25.89 Mn | -200.98 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -200.98 Mn |
| Mar 31, 2026 | -208.27 Mn |
| Dec 31, 2025 | -182.44 Mn |
| Sep 30, 2025 | -306.18 Mn |
| Jun 30, 2025 | -134.37 Mn |
| Mar 31, 2025 | -161.38 Mn |
| Dec 31, 2024 | -153.01 Mn |
| Sep 30, 2024 | -160.55 Mn |
| Jun 30, 2024 | -143.32 Mn |
| Mar 31, 2024 | -135.64 Mn |
| Dec 31, 2023 | -136.90 Mn |
| Sep 30, 2023 | -129.42 Mn |
| Jun 30, 2023 | -128.64 Mn |
| Mar 31, 2023 | -131.29 Mn |
| Dec 31, 2022 | -135.41 Mn |
| Sep 30, 2022 | -142.31 Mn |
| Jun 30, 2022 | -19.82 Mn |
| Mar 31, 2022 | -89.45 Mn |
| Dec 31, 2021 | -31.37 Mn |
| Sep 30, 2021 | -76.13 Mn |